key: cord-0307330-py8qf1z7
authors: Gingerich, Aaron D.; Royer, Fredejah; McCormick, Anna L.; Scasny, Anna; Vidal, Jorge E.; Mousa, Jarrod J.
title: Synergistic protection against secondary pneumococcal infection by human monoclonal antibodies targeting distinct epitopes
date: 2022-04-20
journal: bioRxiv
DOI: 10.1101/2022.04.20.488872
sha: 12ee8ac43ccf4c0e2581d98252d8f147739d08a8
doc_id: 307330
cord_uid: py8qf1z7

Streptococcus pneumoniae persists as a leading cause of bacterial pneumonia despite the widespread use of polysaccharide-based vaccines. The limited serotype coverage of current vaccines has led to increased incidence of non-vaccine serotypes, as well as an increase in antibiotic resistance among these serotypes. Pneumococcal infection often follows a primary viral infection such as influenza virus, which hinders host defense and results in bacterial spread to the lungs. We previously isolated human monoclonal antibodies (mAbs) against the conserved surface antigen pneumococcal histidine triad protein D (PhtD), and we demonstrated that mAbs to this antigen are protective against lethal pneumococcal challenge prophylactically and therapeutically. In this study, we elucidated the mechanism of protection of a protective anti- pneumococcal human mAb, PhtD3, which is mediated by the presence of complement and macrophages in a mouse model of pneumococcal infection. Treatment with mAb PhtD3 reduced blood and lung bacterial burden in mice, and mAb PhtD3 is able to bind to bacteria in the presence of the capsular polysaccharide, indicating exposure of surface PhtD on encapsulated bacteria. In a mouse model of secondary pneumococcal infection, protection mediated by mAb PhtD3 and another mAb targeting a different epitope, PhtD7, was reduced, however, robust protection was restored by combining mAb PhtD3 with mAb PhtD7, indicating a synergistic effect. Overall, these studies provide new insights into anti-pneumococcal mAb protection and demonstrate for the first time that mAbs to pneumococcal surface proteins can protect against secondary pneumococcal infection in the mouse model. Author Summary The persistence of Streptococcus pneumoniae as a leading cause of bacterial pneumonia despite numerous approved pneumococcal vaccines is a serious threat to public health globally. Currently, prophylactic and therapeutic options for Streptococcus pneumoniae are constrained by the limited serotype coverage of vaccines and the emergence of antibiotic resistant strains. An additional hurdle to overcome is the incidence of secondary pneumococcal infection following a viral infection, which leads to increased mortality. Here, we determined the mechanism of action of a monoclonal antibody (mAb) that targets Streptococcus pneumoniae. We found that mAb PhtD3 operates through macrophage and complement mediated functions. mAb PhtD3 was also discovered to reduce bacterial titers in the lungs and blood and bind to a related antigen PhtE. We also tested additional mAbs and discovered that two unique mAbs to the antigen PhtD conferred protection in a pneumococcal-influenza virus co-infection model. Our study provides new insights into the mechanisms and therapeutic potential of mAbs targeting conserved proteins of Streptococcus pneumoniae.

Streptococcus pneumoniae is designated a priority pathogen by the World Health Organization 57 due to widespread infections and high mortality nearing 1 million deaths worldwide each year (1).

Currently, pneumococcal vaccination for disease prevention and antibiotics for disease treatment 59 are widely used, and have been highly successful in reducing the morbidity and mortality 60 associated with pneumococcal infection. However, several factors remain to be addressed that nutrients (17) and attachment sites for S. pneumoniae (18, 19) . Influenza virus alters mucus 83 production and decreases ciliary action, reducing mucociliary clearance of S. pneumoniae (20).

The innate immune response following influenza infection is also impaired. Alveolar macrophage- 

We previously isolated the first human monoclonal antibodies to pneumococcal protein antigens, 93 including the pneumococcal histidine triad protein (PhtD) and pneumococcal surface protein A 94 (PspA) (26). mAbs to PhtD prolonged survival of pneumococcal infected mice when administered 95 before or after infection (26). While in vitro opsonophagocytic assays showed anti-PhtD mAbs 96 lead to an increase in phagocytic activity, the mechanism of protection in vivo remains undefined.

In this study we defined the mechanistic correlation of protection for a human anti-PhtD mAb,

PhtD3, and determined that protection is mediated by macrophages and complement in an 99 intranasal infection model of pneumococcal infection. We also found that bacterial titers in the 100 lungs and blood of infected mice were significantly reduced in mAb PhtD3 treated mouse groups.

Additionally, we discovered that a subset of mAbs to PhtD cross-react with the related 102 pneumococcal histidine triad protein E, and this cross-reactivity was correlated to epitope 103 specificity. Finally, we examined the efficacy of anti-PhtD mAbs in a model of secondary 104 pneumococcal infection and found that individual protective mAbs have reduced efficacy in this 105 model, however, administration of two mAbs targeting nonoverlapping epitopes restores 106 protective efficacy. 

Macrophages were depleted in mice as previously described (28). 5-7 week old C57BL/6 mice 156 were intraperitoneally injected with 2 mg of clodronate liposome (Encapsula NanoSciences) or clodronate liposome or control liposomes. Mice were monitored as above for the prophylaxis 160 studies.

To verify neutrophil and macrophage depletion, a second set of mice treated with RB6-8C5 (14- 

Complement depletion in mice was completed as previously described (28). 5-7 week old 178 C57BL/6 mice (Charles River) were intraperitoneally injected with 0.01 U/g of cobra venom factor 179 one day prior to pneumococcal infection, and mice were intraperitoneally injected with 15 mg/kg 180 of mAb 2 hrs prior to pneumococcal infection. Mice were infected with strain WU2 as above, and 181 on days 1,3, 6, 9, and 12 post infection mice were intraperitoneally injected with 0.01 U/g of cobra 182 venom factor. Mice were monitored as above for the prophylaxis studies. To verify our 183 complement depletion procedure, a second set of mice treated with CVF or PBS were utilized.

Serum was collected from depleted and non-depleted mice at several time points. Murine serum C3 levels were determined as previously described (29). In brief serum from complement depleted 186 and non-depleted mice was used to coat 96-well plates overnight. The plates were then washed 187 1x with PBS containing 0.05% Tween-20 (PBS-T) and blocked for 1 hr at room temperature with 188 blocking buffer (2% nonfat milk, 2% goat serum in 0.05% PBS-T). Plates were washed 3x with 189 PBS-T. Following washing a 1:2000 dilution goat anti-mouse C3 antibody-HRP conjugated 190 (#GC3-90P-Z, ICL, Inc) in blocking buffer was added and incubated for 1 hr at room temperature.

Plates were washed 3x PBST followed by the addition of TMB, and the reaction was stopped with 192 2 M sulfuric acid absorbance was measured at 450nm. 

Bacteria pellets were collected by centrifugation at 6,000 × g for 10 min and frozen at −80 °C.

Thawed E. coli pellets were resuspended in 10 ml of buffer containing 20 mM Tris (pH 7.5) and

218 500 mM NaCl and then lysed by sonication. Cell lysates were centrifuged at 12,000 × g for 30 min, 

Flow binding experiments

The ability of mAbs to bind antigen exposed on the surface of S. pneumoniae in the presence of 236 the CPS was determined by flow cytometry. Bacteria (1x10 7 CFUs) were incubated with 10 µg/mL 

of these mice at various timepoints, which indicates our treatment regimen successfully depleted 319 C3 ( Figure 1H) . Overall, these data indicate the efficacy of mAb PhtD3 is dependent on 320 macrophages and complement as previously described for anti-PhtD mouse mAbs (28).

To determine what role mAb PhtD3 treatment has on mouse bacterial burden, mice were treated breadth, binding to pneumococcal serotype 3 was previously observed (26). Additionally, we included mAb PhtD7, which also targets PhtD and is broadly-reactive, yet binds a conformational 393 epitope located on the C-terminal region of PhtD that does not overlap with mAb PhtD3 (26).

PspA16 was able to significantly prolong survival of mice compared to isotype control mAb and 395 PBS treated mice, 50% vs 0% vs 0% respectively ( Figure 5A ). Mice treated with mAb PhtD7 396 demonstrated significantly higher survival 90% vs 10% compared to isotype control mAb treated 397 mice ( Figure 5B ). As mAb PhtD7 demonstrated robust efficacy in a prophylactic model compared with an isotype control mAb (85% vs 10%) ( Figure 6A ). Based on these data, we next utilized 415 this combination in our co-infection model. We discovered that the combination of both mAbs

PhtD3 and PhtD7 led to a synergistic effect resulting in a robust increase in survival compared to 417 the isotype control mAb treated mice 85% vs 0% respectively ( Figure 6B ).

In this study, we demonstrated that the protective efficacy of the anti-pneumococcal human mAb

PhtD3 is dependent on macrophages and the complement system, but not neutrophils.

Additionally, we demonstrated the protective efficacy of a combination therapy utilizing mAb 

WHO. Who Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed

Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader

Streptococcus pneumoniae serotype 3 associated parapneumonic pleural 549 effusion/empyema after the introduction of PCV13 in Germany. Vaccine

Illustration of 552 pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells

Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS 556

Clin Vaccine Immunol

Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic 561 influenza A (H1N1) -United States

Pulmonary pathologic 564 findings of fatal 2009 pandemic influenza A/H1N1 viral infections

Predominant role of bacterial pneumonia as a 567 cause of death in pandemic influenza: implications for pandemic influenza preparedness

Influenza promotes pneumococcal growth during 570 coinfection by providing host sialylated substrates as a nutrient source. Cell Host 571 Microbe

Immune dysfunction and bacterial coinfections following influenza

Adherence of type I 575

Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 576 virus

Influenza virus infection 578 decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae

Alveolar Macrophage Dysfunction and Thereby Enables Noninvasive Streptococcus 582 pneumoniae to Cause Deadly Pneumonia

Depletion of alveolar macrophages during 585 influenza infection facilitates bacterial superinfections

Both influenza-induced neutrophil dysfunction and 588 neutrophil-independent mechanisms contribute to increased susceptibility to a secondary 589

Streptococcus pneumoniae infection

Effect of antiviral treatment on the outcome of secondary bacterial 591 pneumonia after influenza

Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad 596 Protein Protect against Fatal Pneumococcal Infection

Use of Ly6G-specific 599 monoclonal antibody to deplete neutrophils in mice

Antibodies to PcpA and 601 PhtD protect mice against Streptococcus pneumoniae by a macrophage-and 602 complement-dependent mechanism

MHC class I-specific 604 antibody binding to nonhematopoietic cells drives complement activation to induce 605 transfusion-related acute lung injury in mice

Antibody recognition of the Pneumovirus fusion protein 608 trimer interface

Competitive Dominance 610 within Biofilm Consortia Regulates the Relative Distribution of Pneumococcal 611

Identification 613 and characterization of a novel family of pneumococcal proteins that are protective 614 against sepsis

Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-617

Specific Antibody Alters Streptococcus pneumoniae Gene Expression during

Sequential 623 targeting of interferon pathways for increased host resistance to bacterial superinfection 624 during influenza

Efficacy 626 of a novel

Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind 628 study

Efficacy, 630 safety and immunogenicity of a pneumococcal protein-based vaccine co-administered 631 with 13-valent pneumococcal conjugate vaccine against acute otitis media in young 632 children: A phase IIb randomized study

Human neutrophils kill Streptococcus pneumoniae via serine 634 proteases

The importance of neutrophils in resistance to pneumococcal 636 pneumonia in adult and neonatal mice

The efficacy of pneumococcal 638 capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae 639 requires macrophages

Secondary streptococcal infection 641 following influenza

Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae

Tracheal function during influenza infections

A 648 nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal 649 challenge with pneumococci

Protective properties 651 of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal 652 challenge by five different PspA clades in mice

Immunization of 655 humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that 656 passively protect mice from fatal infection with Streptococcus pneumoniae bearing 657 heterologous PspA

Pan-ebolavirus 659 protective therapy by two multifunctional human antibodies

Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with 663 independent mechanisms

A combination 665 of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus 666 macaques

We thank the International Reagent Resource for the H1N1 A/California/07/2009 influenza virus.

Authors also thank Ana Vidal from the Department of Microbiology and Immunology, University